all report title image
  • Published On : Sep 2022
  • Code : CMI1531
  • Industry : Pharmaceutical
  • Pages : 180
  • Formats :
Ingographics Image

Acute bacterial skin and skin structure infections is a collection of common types of infection including abscesses, cellulitis, and wound infections, which requires an immediate effective antibacterial treatment as part of a timely and careful management.

Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus causing acute bacterial skin and skin structure infections are more challenging to treat due to lack of availability of effective antibiotics. Acute bacterial skin and skin structure infections may be acquired through hospitals, as well as community. Methicillin-resistant Staphylococcus aureus may appear in a community among younger people who had not been previously exposed to hospitals or healthcare institutions, who may instead have been colonized through sporting activities, crowding, and intravenous drug abuse.

Market Dynamics

Market players are acquiring drug distribution rights in a country, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, in March 2020, Sandoz, a pharmaceutical company acquired distribution rights of daptomycin 500mg injection and fosaprepitant 150mg for injection in the U.S. from BE Pharmaceuticals, a pharmaceutical company. This step was taken to strengthen the company's plan to grow its injectable portfolio and contributions in the hospital. Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections.

Increasing research and development by the key players for the development of new drugs to treat global acute bacterial skin and skin structure infections is expected to propel growth of the global acute bacterial skin and skin structure infections market. For instance, on September 28, 2020, TenNor Therapeutics Limited, a global clinical-stage company completed Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNP-2092 to treat acute bacterial skin and skin structure infection in adults.  TNP-2092 was compared to vancomycin in a double-blind randomized, phase-II clinical trial for the treatment of confirmed or suspected Gram-positive ABSSSI. The study has been completed, and results are awaited. 

Key features of the study:

  • This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global acute bacterial skin and skin structure infections market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc    
  • Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global acute bacterial skin and skin structure infections market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market

Detailed Segmentation:

  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type:
    • Oral & Parenteral Antibiotics
      • Oritavancin
      • Delafloxacin
      • Vancomycin
      • Daptomycin
      • Dalbavancin
      • Ceftaroline
      • Linezolid
      • Tedizolid
      • Clindamycin
      • Others (Rifampin, Doxycycline, Minocycline, Trimethoprim-Sulfa Methoxazol, etc.)
    • Topical Antibiotics
      • Hydrogen Peroxide
      • Fusidic Acid
      • Mupirocin
      • Retapamulin
      • Povidone-Iodine
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type:
    • Hospital Acquired ABSSSI
    • Community Acquired ABSSSI
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration:
    • Oral
    • Parenteral
    • Topical
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Fresenius SE & Co. KGaA *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Amneal Pharmaceuticals LLC
    • Intas Pharmaceuticals Ltd.
    • Cadila Healthcare Ltd.
    • Glenmark Pharmaceuticals Ltd,
    • GlaxoSmithKline plc.
    • Sun Pharmaceutical Industries Ltd.
    • Sandoz Inc.
    • Aurobindo Pharma Ltd.
    • AbbVie, Inc.
    • Melinta Therapeutics, Inc.
    • Accord Healthcare Ltd.
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Paratek Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Infection Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Recent Product Launch/Approval
    • Epidemiology
    • Mergers and Acquisitions
  4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (Covid-19) Pandemic
    • Impact on Supply Chain
    • Impact on Research and Development
    • Government Initiatives
  5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2017-2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 - 2030
      • Segment Trends
    • Oral & Parenteral Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
      • Oritavancin
      • Delafloxacin
      • Vancomycin
      • Daptomycin
      • Dalbavancin
      • Ceftaroline
      • Linezolid
      • Tedizolid
      • Clindamycin
      • Others (Rifampin, Doxycycline, Minocycline, Trimethoprim-Sulfa Methoxazol, etc.)
    • Topical Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
      • Hydrogen Peroxide
      • Fusidic Acid
      • Mupirocin
      • Retapamulin
      • Povidone-Iodine
  6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 - 2030
      • Segment Trends
    • Hospital Acquired ABSSSI
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Community Acquired ABSSSI
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 - 2030
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 - 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Infection Type, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 - 2030 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Company Profiles
      • Fresenius SE & Co. KGaA
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Amneal Pharmaceuticals LLC
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Intas Pharmaceuticals Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cadila Healthcare Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Glenmark Pharmaceuticals Ltd
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sandoz Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Aurobindo Pharma Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AbbVie, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Melinta Therapeutics, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Accord Healthcare Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Paratek Pharmaceuticals, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 44 market data tables and 59 figures on "Global Acute Bacterial Skin and Skin Structure Infections Market” - Forecast to 2030.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo